LDLR-fucosyltransferaseAS fusion protein (312-320)

LDLR-fucosyltransferaseAS fusion protein (312-320) is a specialized recombinant peptide construct that integrates a segment of the low-density lipoprotein receptor (LDLR) with the catalytic domain of a fucosyltransferase enzyme, specifically encompassing amino acid residues 312 to 320. This fusion protein is engineered to facilitate the study of protein-glycan interactions, post-translational modifications, and enzyme-substrate specificity within the context of glycosylation research. Its unique structure provides a valuable model for dissecting the functional interplay between receptor domains and glycosyltransferase activity, making it highly relevant for investigations in glycobiology, molecular cell biology, and protein engineering.

Enzyme mechanism studies: The fusion protein serves as an effective tool for elucidating the catalytic mechanisms of fucosyltransferases when linked to protein substrates. Researchers can employ this construct to probe how the LDLR segment influences enzyme orientation, substrate recognition, and fucosylation efficiency. By analyzing enzyme kinetics and substrate specificity using this model, scientists gain deeper insights into the regulatory factors that govern glycosyltransferase-mediated modifications in eukaryotic systems.

Protein-glycan interaction analysis: As a chimeric molecule combining a receptor domain with a glycosyltransferase, the fusion protein enables detailed investigations into the molecular determinants of protein-glycan binding. It can be used in affinity assays, surface plasmon resonance, or other biophysical techniques to assess how fucosylation alters the interaction landscape of LDLR fragments. Such studies are critical for understanding the role of glycosylation in modulating receptor function and cellular signaling pathways.

Glycoprotein engineering: The recombinant nature of the fusion protein allows it to be incorporated into synthetic biology workflows aimed at designing novel glycoproteins with tailored properties. By leveraging the modularity of the LDLR and fucosyltransferase domains, researchers can explore strategies for site-specific glycan installation or modification. This approach supports the development of engineered proteins for use in biomaterials, diagnostics, or as research tools for probing glycan-dependent biological processes.

Analytical method development: The defined sequence and dual-domain architecture of the fusion protein make it a suitable standard or control in analytical assays designed to detect fucosylation or monitor glycosyltransferase activity. It can be utilized in mass spectrometry, HPLC, or immunoassay platforms to calibrate detection sensitivity or validate analytical workflows. Such applications are essential for ensuring accuracy and reproducibility in glycoproteomics and enzymology research.

Cellular pathway elucidation: By introducing the fusion protein into cellular or cell-free systems, scientists can study the downstream effects of LDLR glycosylation on intracellular trafficking, receptor-mediated endocytosis, or signal transduction. The construct enables controlled experimentation on how site-specific fucosylation impacts receptor processing, localization, and function, thereby contributing to a more comprehensive understanding of glycan-mediated regulation in complex biological networks.

1. Emu oil in combination with other active ingredients for treating skin imperfections

2. Olfactory receptor based piezoelectric biosensors for detection of alcohols related to food safety applications

3. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

4. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

5. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors